- Home
- CVKD vs CYCN Comparison
CVKD vs CYCN Comparison
Compare CVKD & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVKD | CYCN |
|---|---|---|
| Founded | 2022 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 5.6M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | CVKD | CYCN |
|---|---|---|
| Price | $5.42 | $1.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | ★ 52.2K | 36.2K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.91 | $1.03 |
| 52 Week High | $19.03 | $3.79 |
Technical Indicators
Market Signals| Indicator | CVKD | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 30.37 | 63.06 |
| Support Level | $5.13 | $1.31 |
| Resistance Level | $14.21 | $1.61 |
| Average True Range (ATR) | 0.60 | 0.13 |
| MACD | -0.28 | 0.02 |
| Stochastic Oscillator | 14.08 | 79.99 |
Price Performance
Historical ComparisonAbout CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.